Bowman Consulting Group reports Q1 2026 results on May 6 with a stock that has snapped back hard — but with options positioning at its most defensive reading of the past year, and a founder who has been a steady seller into the rally.
The price move into the print is striking. Shares rose nearly 15% over the past month to $34.00, including a 9.4% gain on the week and a 4.7% jump on the final day before the report. That recovery looks impressive in isolation, but the two most recent earnings reactions were both sharply negative: the stock fell 11.1% on the day and 14.3% over the following five days after the last print in early March. The print before that produced a similar pattern — down 2.8% on the day and 7.5% over five sessions. The stock is still down roughly 2% year-to-date, meaning the current bounce is still working against a weak start to 2026.
Options positioning has moved to its most cautious extreme of the past year heading into the release. The put/call ratio climbed to 32.6 — the 52-week high — against a 20-day average of 24.2. That is nearly one standard deviation above recent norms, a signal that whatever options activity exists on this small-cap name has tilted firmly toward protection. The shift is notable because it accelerated only in late April, coinciding almost exactly with the price rebound.
Short interest is a secondary rather than primary concern here. At 2.4% of the free float, the short position is modest by any standard. Borrowing costs remain near rock-bottom at 0.59% annually, and borrow availability is ample — well below its 52-week tightness peak. Days to cover runs just over 4, and the ORTEX short score of 36.6 ranks in the 38th percentile, signalling no particular conviction from the short side.
The ownership and insider picture adds an important nuance. Founder, Chairman and CEO Gary Bowman holds a 13.2% stake but sold 20,000 shares on April 22 for roughly $614,000 — his second disposal block in three months. Combined with earlier February sales, net insider activity has been negative on a 90-day basis despite a share award in between. That pattern of routine trimming from the top is not alarming, but it sits at odds with the bullish tone of the five-analyst buy consensus, which carries a mean target of $43.58 — implying roughly 28% upside from current levels. The most recent analyst action of note was Baird lowering its target to $37 from $43 in early March, immediately after the last poor earnings reaction, while maintaining its Outperform rating. JP Morgan, which initiated at Neutral in January with a $40 target, sits in a more cautious camp. Taken together, the Street is constructive but has been marking down expectations.
The Q1 print will test whether the recent share-price recovery rests on improving fundamentals or simply reflects sector-wide momentum — peer names ENGS, LMB and ORN all gained between 21% and 34% on the week, suggesting the broader group has been lifted by the same tide.
See the live data behind this article on ORTEX.
Open BWMN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
